These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12171558)

  • 21. Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor.
    Kany AM; Sikandar A; Yahiaoui S; Haupenthal J; Walter I; Empting M; Köhnke J; Hartmann RW
    ACS Chem Biol; 2018 Sep; 13(9):2449-2455. PubMed ID: 30088919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide deformylase inhibitors with non-peptide scaffold: synthesis and structure-activity relationships.
    Lee SK; Choi KH; Lee SJ; Lee JS; Park JY; Kim BM; Lee BJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):133-6. PubMed ID: 21146987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
    Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor.
    Clements JM; Beckett RP; Brown A; Catlin G; Lobell M; Palan S; Thomas W; Whittaker M; Wood S; Salama S; Baker PJ; Rodgers HF; Barynin V; Rice DW; Hunter MG
    Antimicrob Agents Chemother; 2001 Feb; 45(2):563-70. PubMed ID: 11158755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, biological evaluation and molecular docking studies of benzyloxyacetohydroxamic acids as LpxC inhibitors.
    Szermerski M; Melesina J; Wichapong K; Löppenberg M; Jose J; Sippl W; Holl R
    Bioorg Med Chem; 2014 Feb; 22(3):1016-28. PubMed ID: 24412340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.
    McAllister LA; Montgomery JI; Abramite JA; Reilly U; Brown MF; Chen JM; Barham RA; Che Y; Chung SW; Menard CA; Mitton-Fry M; Mullins LM; Noe MC; O'Donnell JP; Oliver RM; Penzien JB; Plummer M; Price LM; Shanmugasundaram V; Tomaras AP; Uccello DP
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6832-8. PubMed ID: 23046961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
    Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
    Xue CB; Voss ME; Nelson DJ; Duan JJ; Cherney RJ; Jacobson IC; He X; Roderick J; Chen L; Corbett RL; Wang L; Meyer DT; Kennedy K; DeGradodagger WF; Hardman KD; Teleha CA; Jaffee BD; Liu RQ; Copeland RA; Covington MB; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Aug; 44(16):2636-60. PubMed ID: 11472217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design.
    Tholander F; Muroya A; Roques BP; Fournié-Zaluski MC; Thunnissen MM; Haeggström JZ
    Chem Biol; 2008 Sep; 15(9):920-9. PubMed ID: 18804029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
    Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
    Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse hydroxamate-based selective TACE inhibitors.
    Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
    Rossello A; Nuti E; Carelli P; Orlandini E; Macchia M; Nencetti S; Zandomeneghi M; Balzano F; Uccello Barretta G; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1321-6. PubMed ID: 15713379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues.
    Dankwardt SM; Martin RL; Chan CS; Van Wart HE; Walker KA; Delaet NG; Robinson LA
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2085-8. PubMed ID: 11514144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
    Chen JM; Jin G; Sung A; Levin JI
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel approaches to antimicrobial therapy: peptide deformylase.
    Waller AS; Clements JM
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):785-92. PubMed ID: 12630299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, Synthesis, and Biological Evaluation of Vanillin Hydroxamic Acid Derivatives as Novel Peptide Deformylase Inhibitors.
    Gao J; Qiu S; Liang L; Hao Z; Zhou Q; Wang F; Mou J; Lin Q
    Curr Comput Aided Drug Des; 2018; 14(1):95-101. PubMed ID: 28606047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.